Entest Group Inc

[JokersWild12]

The fact that Zander filed for the composition of matter patent indicates that they have a compound as a result of their animal NR2F6 testing that they believe can be used to treat canine and feline cancer. As compared to Regen's NR2F6 development for human use Entest is farther ahead and will have an easier pathway than for human use in terms of testing and expense and speed to market. As indicated there are more milestones but its encouraging anyway that a patent was filed for a compound. In the end who knows if it will succeed, what the timeline will really be or if expense is prohibitive to bring anything to market. If it works however it will have value and can be licensed or sold out right. IMO. GL.